

### Remarks

#### *Claim amendments:*

In claims 1 and 4, for consistency, oxoplatin was amended to cis-oxoplatin (see p. 4, lines 6 and 7 of the specification and page 4, lines 19 to 21 of the original PCT application text). Claim 4 was amended to incorporate the limitations of the kit claim it previously depended from.

#### *Response to Restriction Requirement:*

Claims 1, 2, 4 to 13 and 15 to 22 are pending in this application of which claims 1 and 4 are in independent form.

The Office restricted the claims into four groups:

Group I, claim(s) 1 and 2, drawn to a kit.

Group II, claim(s) 4-13, drawn to a pharmaceutical agent.

Group III, claim(s) 15, drawn to a method of producing a pharmaceutical agent for the treatment of tumors.

Group IV, claim(s) 16-22, drawn to a method for the prophylaxis or therapy of cancerous diseases.

Applicant elects, with traverse, the pharmaceutical agent of group II, claims 4 to 13. Applicant would like to thank the Office for advising applicant about the possibility of rejoinder of the product and process claims. In this context, applicant would like to point out the now more clearly recited limitations of the elected pharmaceutical agent claims. These limitations are now positively recited in the kit and pharmaceutical agent claims. The Office is respectfully requested to consider these limitations in its further determination of the common technical feature in particular of the kit and pharmaceutical agent claims.

No fees are believed to be due with this response. However, the Office is authorized to charge undersigned's deposit account 50-3135 as required.

Respectfully submitted,

By /Joyce v. Natzmer/  
Joyce von Natzmer  
Registration No. 48,120  
**Customer No. 46002**  
Telephone: (301) 657-1282

June 19, 2008